



THE WORLD'S LEADER IN FIGHTING OVARIAN CANCER





THANK YOU

FROM OUR PRESIDENT & CEO

Dear Friends,

As we look back on 2020, I am struck by how dramatically our world changed, how quickly we all had to respond to a new and ever-fluid reality, and how prescient we were just several months prior as we planned our budget.

Little did we know a pandemic would make in-person events all but impossible when we decided, in the latter months of 2019, to shift away from relying on signature events for revenue, and lean harder into sponsorships, peer-to-peer fundraising and individual donor support. Yet, although we were preparing for this shift, we still had to get creative in order to meet the needs of our community when we went into lockdown.

While the world, rightly, was focused on COVID-19, we kept a laser focus on our mission of finding and funding cutting-edge ovarian cancer research. The prevalence of this disease did not wane; the needs of those dealing with diagnosis and treatment did not diminish. And neither did our commitment. We found new ways to keep up momentum.

We increased our communications, concerned by the fact that an ovarian cancer diagnosis can be an isolating experience in and of itself, without adding in this new concept of social distancing. Our oncology social worker responded to a huge increase in calls in the early spring of 2020, a volume that continued throughout the year. Like the rest of the world, we learned how to 'go virtual'—from hosting fundraising fitness events on Zoom, to hosting a conference that reached twice as many people as it ever had before. We created a series of online support groups to foster much-needed connection, and discovered that virtual presentations allowed our Survivors Teaching Students volunteers to connect with many more rising healthcare professionals, in many more schools, than we had previously been able to reach.

And throughout it all, you stood by our side and kept up a level of support that helped us meet these challenges head on. As we look back on all that we accomplished in 2020, we are grateful to you, our supporters, for your generosity, your tenacity, and your shared commitment to envisioning a world without ovarian cancer.

We are pleased to share these highlights with you, showing the breadth of our work as the world's largest ovarian cancer charity. We invite you to visit our website (ocrahope.org) or follow us on social media (@ocrahope) to stay up to date on all the latest we have to share.

On behalf of everyone at OCRA, thank you.

Sincerely,


Audra L. Moran
President & CEO

2020

BY THE NUMBERS

FUNDED 22
SCIENTISTS

\$6.6M



65

ADVOCATE LEADERS
REPRESENTED
41 STATES



ADVOCATES INFLUENCED **LARGEST**
FEDERAL INVESTMENT EVER OF

\$243M



7 ACTION ALERTS RESULTED IN

10,595



MESSAGES TO CONGRESS

948 TRAINED
VOLUNTEERS
REACHED



10,000

RISING HEALTHCARE
PROFESSIONALS AT
351 SCHOOLS

FIELDLED



778 PATIENT SUPPORT CALLS

85% INCREASE FROM YEAR PRIOR

WOMAN TO WOMAN MENTORS ASSISTED

270



PATIENTS AROUND THE U.S.



64,811

MEMBERS IN OUR
INSPIRE ONLINE COMMUNITY


\$75K

IN FINANCIAL ASSISTANCE DISTRIBUTED TO
PATIENTS THROUGHOUT THE COUNTRY



650

PEOPLE FROM THE U.S. AND AROUND
THE WORLD ATTENDED OUR **OVARIAN
CANCER NATIONAL CONFERENCE**



RESEARCH

PARTNERING WITH
SCIENTISTS TO ERADICATE
OVARIAN CANCER



RESEARCH



OCRA is the largest non-government funder of ovarian cancer research and has the longest track record of impact. To date, we have invested \$110M to jumpstart promising research and hasten desperately needed breakthroughs. Every day, OCRA-funded researchers are finding new ways to treat, prevent and ultimately cure ovarian cancer.

2020 OCRA GRANTEES:

- ⊕ Identified a new drug that could greatly increase survival rates of ovarian cancer patients
- ⊕ Completed a Phase Ib Trial to increase the efficacy of PARP inhibitors in breast and epithelial ovarian cancers, and found that a Phase II trial was warranted
- ⊕ Found 34 genes were connected to women developing the earliest stages of ovarian cancer
- ⊕ Published a study which found success targeting cancer cells by combining two existing classes of drugs that target the cells' ability to divide, dramatically increasing the drug's capacity to kill cancer cells while largely sparing healthy ones
- ⊕ Published a study which defined a combination therapy that delays tumor growth significantly, and will inform the design of a clinical trial to improve the frequency and magnitude of ovarian cancer patient responses to immunotherapy



IN 2020 WE FUNDED
22 INVESTIGATORS
AWARDING
\$6.6 MILLION
IN GRANTS

COLLABORATIVE RESEARCH DEVELOPMENT GRANT

Ugo Cavallaro, PhD

Fondazione Istituto Europeo di Oncologia e Centro Cardiologico Fondazione Monzino
Interplay Between Ovarian Cancer Stem Cells and the Tumor Microenvironment

Andrew K. Godwin, PhD

University of Kansas Medical Center Research Institute
Tumor-Derived Extracellular Vesicle in Ovarian Cancer

Sandra Orsulic, PhD

UCLA School of Medicine
Co-Evolution of Epithelial Ovarian Cancer and Tumor Stroma

Sohrab Shah, PhD

Memorial Sloan Kettering Cancer Center
Profiling Co-Evolution of Ovarian Cancer and its Immune Microenvironment

LIZ TILBERIS EARLY CAREER AWARD

James Duncan, PhD

Fox Chase Cancer Center
Exploring PROTAC-Mediated Degradation of BRD4 in Ovarian Cancer

Mark Eckert, PhD

University of Chicago
The Fate and Function of Adipocytes in Ovarian Cancer Metastasis

Sudipto Ganguly, PhD

Johns Hopkins University
Characterizing a Novel Checkpoint Axis in High-Grade Serous Ovarian Cancer

Brooke Howitt, MD

Stanford University
Identifying the Cell of Origin for Ovarian High-Grade Serous Carcinoma

Sunila Pradeep, PhD

Medical College of Wisconsin
Epigenetic Causes of Acquired Resistance of Anti-VEGF Therapy

Nidhi Sahni, PhD

MD Anderson Cancer Center
Systems Approach for PARP-based Novel Combination Therapy in Ovarian Cancer

Boris Winterhoff, MD

University of Minnesota Twin Cities
Precision Medicine in Ovarian Cancer: Using Single Cell Analysis

Dmitriy Zamarin, MD, PhD

Memorial Sloan Kettering Cancer Center

Chromatin Remodeling and Immunotherapy in Ovarian Cancer

ANN AND SOL SCHREIBER MENTORED INVESTIGATOR AWARD

David Chapel, MD

Brigham and Women's Hospital

The Migratory Precursor and Serous Carcinogenesis

Yilun Deng, PhD

University of Texas Health Science Center at San Antonio

CD122-Selective IL-2 Complexes as Novel Ovarian Cancer Therapy

Elizabeth Lee, MD

Dana-Farber Cancer Institute

Phase II Trial of Gemcitabine+ATR Inhibitor: Translational Studies

Jianhuang Lin, PhD

The Wistar Institute

Targeting ER Stress Pathway in CARM1-Expressing Ovarian Cancer

Duygu Ozmadenci, PhD

University of California San Diego

Sensitizing Ovarian Cancer to Immunotherapies

Elizabeth Raupach, PhD

The Translational Genomics Research Institute

Oncogenic Consequences of Altered SWI/SNF-RNA Interactions in SCCOHT

Camilla Salvagno, PhD

Weill Medical College of Cornell University

Dissecting How ER Stress Responses Shape Ovarian Cancer Immuno-Environments

Janice Santiago, PhD

MD Anderson Cancer Center

Crizotinib Improves the Therapeutic Efficacy of Olaparib in Ovarian Cancer

Ignacio Vázquez-García, PhD

Memorial Sloan Kettering Cancer Center

Co-Evolution and Dynamics of Malignant and Immune Cells in Ovarian Cancer

Morozov Yaroslav, PhD

University of Pennsylvania

The BRCA1-A as a Determinant of Chemotherapy Response in ATM Mutated Cells



ADVOCACY

ENGAGING WITH
POLICYMAKERS TO KEEP
THIS FIGHT A PRIORITY



ADVOCACY

We are *the* voice for the ovarian cancer community, working with legislators to ensure federal ovarian cancer research and education, patient safety, and access to high-quality care are protected on Capitol Hill.



In 2020, 84 ovarian cancer advocates from 43 states gathered in Washington, DC, to meet with their elected officials and ask them to sign onto an effort to dramatically increase funding for the Ovarian Cancer Research Program at the Department of Defense. We were fortunate to be able to meet in person, just before the halls of Congress closed to visitors and employees due to the global pandemic.



Our Advocate Leaders program grew from 50 members to 65 members representing 41 states and the District of Columbia.

We helped pass a critical bill expanding access to clinical trials and pushed for expansion of Johanna's Law, The Gynecologic Cancer Education and Awareness Act, that would allow the program to reach more people across the country.



In addition, we sent out seven Action Alerts, resulting in 10,595 messages to Congress.

Our targeted legislative campaigns helped lead to a record federal government spending of \$243 million on ovarian cancer research and awareness programs.

We also change the way future healthcare professionals recognize ovarian cancer through our Survivors Teaching Students program.

Shortly into the year, medical schools across the country went virtual. That didn't stop our Survivors Teaching Students program.



We trained 157 volunteers, bringing our team to 948 individuals committed to sharing their stories of diagnosis and treatment—virtually—with 9,901 rising medical professionals at 351 schools and institutions around the U.S.

Volunteers who would otherwise not have been able to go into a classroom were able to engage with students—three women presented from the hospital, while undergoing chemo—deepening the impact of their personal stories and experiences. And OCRA was able to 'visit' new schools, including institutions in Rhode Island for the first time since inception of the program, increasing our reach to the medical professionals of tomorrow.





PATIENT SUPPORT

STANDING TOGETHER WITH
EVERY PERSON TOUCHED
BY THE DISEASE



PATIENT SUPPORT



Our programs help people navigate an overwhelming diagnosis, supporting patients and their families when and where they need it the most. Our Woman to Woman peer support program pairs newly diagnosed patients with survivors who provide hope and insight, and our Ovarian Cancer National Conference brings survivors together to share knowledge and build community.

It is not surprising that as life in lockdown became a reality, outreach to OCRA's patient support line jumped dramatically. In the first three months of 2020 alone, we had a total of 182 calls, compared to 419 calls in all of 2019. Throughout 2020, we received 778 individual calls, an approximate 85% increase from the year before.



Furthermore, OCRA established two new sites for Woman to Woman programs, bringing the total number of sites to 45. And we trained 13 Woman to Woman mentors.



Our oncology social worker also oversaw the growth of OCRA's Inspire Online Community, which comprises 64,811 members and has grown nearly 20% from the year prior.

In response to the isolation many felt during COVID, we launched Staying Connected, a weekly online support group, in April 2020. Four months later, in August, we expanded

from once a week to three times a week, due to rising demand. In our first year of programming, we had 689 registrants, creating a remarkable community of information, support, and encouragement.

Four months before our 2020 Ovarian Cancer National Conference was to be held in Washington, DC, we had to pivot to a virtual format.



We held our conference in September, during Ovarian Cancer Awareness Month and one of our biggest fundraising seasons of the year, with 650 registrants joining together (online) from across the U.S. and from six countries.

This was more than double our usual number of attendees, and for four days, patients, survivors, family members and experts in the field delved into an array of topics and built community, despite not being in person.

TUESDAY, SEPTEMBER 29
 All times noted in Eastern Time
 11:00 AM – 12:00 PM Lobby Open for Networking
 12:00 PM – 1:30 PM Opening Ceremony
 1:30 PM – 2:30 PM Gail Baird Exhibit Hall—Live Exhibitor Hours
 2:45 PM – 3:45 PM Mello Abrams Lecture: What's New in Ovarian Cancer Research and Treatment
 3:45 PM – 5:00 PM Gail Baird Exhibit Hall—Live Exhibitor Hours
 6:00 PM – 6:30 PM Live Q&A with Stephanie Wethington, MD, MSc, about Managing Recurrence (follow up to breakout session listed below)
 6:30 PM – 8:30 PM Virtual Networking Meet-Up Sessions
 Check website for specific group information
ON-DEMAND BREAKOUT SESSIONS INCLUDE:
 • Clinical Trials 101
 • Impact of the Pandemic on Quality of Life for Those with Ovarian Cancer
 • Managing Recurrence
 • Navigating the Financial Fallout from Cancer
 • Newly Diagnosed: Ovarian Cancer 101
ON-DEMAND WELLNESS SESSIONS INCLUDE:
 • Conscious Breathing Practice
 • Yoga

WEDNESDAY, SEPTEMBER 30
 11:00 AM – 12:00 PM Lobby Open for Networking
 12:00 PM – 1:00 PM All About PARPs & Maintenance Therapy
 1:00 PM – 2:00 PM Gail Baird Exhibit Hall—Live Exhibitor Hours
 1:30 PM – 2:30 PM The Future of Ovarian Cancer Clinical Trials: Lessons Learned from the COVID-19 Experience
 2:30 PM – 3:30 PM Live Breakout: Survivors Teaching Students Volunteer Meeting (For current STS volunteers only)

THURSDAY, OCTOBER 1
 3:00 PM – 5:00 PM Gail Baird Exhibit Hall—Live Exhibitor Hours
 3:30 PM – 4:30 PM Live Breakout: Best Practices in Leadership and Fundraising (for OCRA Community Partners only)
 3:30 PM – 4:30 PM Live Breakout: Woman to Woman Info Session
 4:30 PM – 5:00 PM Live Q&A with Elizabeth Swisher, MD, about Genetic Testing, Counseling, and what the MAGENTA Trial Means for You (follow up to breakout session listed below)
 6:30 PM – 8:00 PM Teal Takeover Party
ON-DEMAND BREAKOUT SESSIONS INCLUDE:
 • Genetic Testing, Counseling, and what the MAGENTA Trial Means for You
 • How to Talk About Genetic Testing and Precision Oncology (And Why It's So Confusing)
 • Living with Ovarian Cancer: How Palliative Care Can Help
 • Racial Disparities in Ovarian Cancer
ON-DEMAND WELLNESS SESSIONS INCLUDE:
 • Healthy Cooking Demo with Elle Simone from America's Test Kitchen
 • Pilates

FRIDAY, OCTOBER 2
 6:30 PM – 8:30 PM Virtual Networking Meet-Up Sessions
 Check website for specific group information
ON-DEMAND BREAKOUT SESSIONS INCLUDE:
 • Advanced Care Planning: Evolving Hope
 • Integrative Medicine for Ovarian Cancer
 • Medical Cannabis: What You Need to Know
 • Ovarian Cancer Care During COVID-19: New Standards and Practices
 • Rare Ovarian Cancers: What's New
ON-DEMAND WELLNESS SESSIONS INCLUDE:
 • Guided Meditation
 • Zumba

11:00 AM – 12:00 PM Lobby Open for Networking
 12:00 PM – 1:00 PM Ask the Experts Part One
 1:00 PM – 2:00 PM Gail Baird Exhibit Hall—Live Exhibitor Hours
 2:15 PM – 3:15 PM Ask the Experts Part Two
 3:30 PM – 5:00 PM Gail Baird Exhibit Hall—Live Exhibitor Hours
 4:00 PM – 4:30 PM Live Q&A with Harpreet Gujral, DNP, FNP-BC, about Integrative Medicine for Ovarian Cancer (follow up to breakout session listed below)
 4:30 PM – 5:30 PM Live Breakout: Want to Fundraise for OCRA? Become an OCRA Hero!
 5:30 PM – 6:30 PM Live Breakout: Survivors Teaching Students Info Session

11:00 AM – 12:00 PM Lobby Open for Networking
 12:00 PM – 1:00 PM General Session TBD
 1:00 PM – 3:00 PM Gail Baird Exhibit Hall—Live Exhibitor Hours
 2:00 PM – 3:00 PM Live Breakout: Advocacy at OCRA: Introduction and Office Hours
 3:00 PM – 3:30 PM Closing Ceremony
ON-DEMAND BREAKOUT SESSIONS INCLUDE:
 • Addressing Health Disparities Through Advocacy
 • Balancing Work & Cancer
 • Immunotherapy for Ovarian Cancer
 • Improving Ovarian Cancer Risk Prediction: The Ovarian Cancer Association Consortium
 • Sexuality and Intimacy After Cancer
ON-DEMAND WELLNESS SESSIONS INCLUDE:
 • High-Intensity Interval Training
 • Yoga

CONFERENCE URL: ocrahope.org/unitingforhope
 PASSWORD: hope2020

BOARD OF DIRECTORS

as of February 2022

EXECUTIVE COMMITTEE

John W. Hansbury, Esq., Chair

Dana L. Mark, Esq., Secretary

Robin S. Cohen, Vice President

Tom Liebman, Director

Mark Tessar, CPA, CIA, Treasurer

Matthew Neal Miller, Director

started 12/3/2020

Jennifer McCahill, Treasurer

ended 12/3/2020

BOARD MEMBERS

Mona Baird

Patricia Goldman

John Orrico

Susan D. Bazaar

Carol J. Hamilton

Lisa Schreiber

Jeannette Chang

Caroline Hirsch

Elle Simone Scott

Carmel J. Cohen, MD

Veronica Jordan, PhD

Chris Tilberis

Mei-Li da Silva Vint, Esq.

Edward Labaton, Esq.

Robin Zarel

Andrew Feuerstein, Esq.

Ylaine G. Mayer

Shelley Golden

Chris Newcomb

LEADERSHIP COUNCIL

Judith Abrams

Terri McKnight, CPA

Diane Rader O'Connor

SCIENTIFIC ADVISORY COMMITTEE

as of February 2022

Ronald Alvarez, MD, MBA, CHAIR (2016-present)
Vanderbilt University Medical Center, Nashville, TN

Deborah Armstrong, MD (2016-present)
Johns Hopkins School of Medicine, Baltimore, MD

Robert C. Bast, Jr., MD (1997-present)
MD Anderson Cancer Center, Houston, TX

Andrew Berchuck, MD, (2000-present)
Duke Comprehensive Cancer Center, Durham, NC

Jonathan S. Berek, MD, MMS (1997-present)
Stanford University School of Medicine, Palo Alto, CA

Molly Brewer, DVM, MD, MS (2004-present)
*University of Connecticut Health Center,
Farmington, CT*

Ronald Buckanovich, MD, PhD (2013-present)
Magee-Womens Research Institute, Pittsburgh, PA

Robert Coleman, MD (2016-present)
MD Anderson Cancer Center, Houston, TX

Annie Ellis (2016-present)
Patient Advocate

Katherine Fuh, MD, PhD (2021-present)
Washington University, St. Louis, MO

Ellen Goode, PhD (2019-present)
Mayo Clinic, Rochester, NY

Beth Karlan, MD (2019-present)
UCLA Medical Center, Los Angeles, CA

Dineo Khabele, MD (2015-present)
*Washington University School of Medicine,
St. Louis, MO*

Susan Leighton, MA (2021-present)
Patient Advocate

Ernst Lengyel, MD, PhD (2013-present)
University of Chicago, Chicago, IL

Ursula Matulonis, MD (2014-present)
Dana-Farber Cancer Institute, Boston, MA

Kathleen Moore, MD, MS (2021-present)
University of Oklahoma, OK City, OK

Carolyn Muller, MD, FACOG (2021-present)
University of New Mexico, NM

Kenneth Nephew, PhD (2014-present)
Indiana University, Bloomington, IN

Celeste Leigh Pearce, PhD, MPH (2015-present)
University of Michigan, Ann Arbor, MI

Kunle Odunsi, MD, PhD (2014-present)
*Roswell Park Comprehensive Cancer Center,
Buffalo, NY*

Sandra Orsulic, PhD (2011-present)
*UCLA David Geffen School of Medicine,
Los Angeles, CA*

Daniel Powell, Jr., PhD (2015-present)
University of Pennsylvania, Philadelphia, PA

Stephen Rubin, MD (2000-present)
Fox Chase Cancer Center, Philadelphia, PA

Carolyn D. Runowicz, MD (1997-present)
Florida International University, Miami, FL

Ie-Ming Shih, MD, PhD (2013-present)
*Johns Hopkins University School of Medicine,
Baltimore, MD*

Anil Sood, MD (2016-present)
MD Anderson Cancer Center, Houston, TX

Shelley Tworoger, PhD (2019-present)
Moffit Cancer Center, Tampa, FL

Jason Wright, MD (2021-present)
Columbia University Medical Center, NY, NY

STAFF

as of February 2022

Audra Moran

President & CEO

Bibi Ali

Vice President, Finance

Dilara Ally

Social Work Intern

Jorge Calderon

Manager, Finance & Operations

Erin Cassin

Manager, Social Media & Content

Vanessa Cramer

Director, Policy

Sarah DeFeo

Vice President, Scientific Affairs & Programs

Bridget Gabbe

Social Work Intern

Sarah Holbert

Ann Kolker Advocacy Fellow

Jessica Hughson-Andrade

Director, Strategic Alliances

Susan Leighton

*National Program Manager, Survivors Teaching Students
(Consultant)*

Deb Levy

Vice President, Marketing & Communications

Kim Liao

Senior Associate, Development

Diana Maynard

Associate Director, Events

Kristin McGowan

Director, Grants & Scientific Affairs

Tracy Moore, LCSW

*Oncology Social Worker, Patient Support
(Consultant)*

Chad Ramsey

Vice President, Policy

Rachel Schwimmer

Coordinator, Development

Nikki Wargo

Senior Director, Development

Lindsey Weeks

Director, Digital Communications

Jon Zeidman

Vice President, Development

FINANCIAL STATEMENT

	2020
Total Revenue & Support	9,518,789
Expenses	
Program Services	
Research	4,638,685
Conference	544,450
Education, Support and Advocacy	1,670,122
Total Program Services	6,853,257
Fundraising	1,136,552
Administrative	897,382
Total Expenses	8,887,191
Ending Net Assets	18,999,892

